While the loss of a single allele of TSC1 or TSC2 may be sufficient to induce certain clinical features of TSC, such as neuropsychiatric changes, the development of hamartomas appears to require an additional somatic inhibitory mutation, termed a second hit, in the remaining allele. Here, TSC1 is linked to tuberous sclerosis.